Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Sep 06, 2023 (filed on Sep 06, 2023)Insider Name:Tomsche David ScottOwnership Type:Direct OwnershipSecurities:Common stock $0.10 per value per shareNature of Transaction:D - Disposition to issuer under Rule 16b-3(e)# or value acquired/disposed of:3,100Price:$4.75
-
Jun 28, 2023 (filed on Aug 30, 2023)Insider Name:Gathagan Bryan K.Ownership Type:Direct OwnershipSecurities:Non-Qualified Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:15,000Price:$5.11
Filings by filing date
-
Sep 06, 2023 (filed on Sep 06, 2023)Insider Name:Tomsche David ScottOwnership Type:Direct OwnershipSecurities:Common stock $0.10 per value per shareNature of Transaction:D - Disposition to issuer under Rule 16b-3(e)# or value acquired/disposed of:3,100Price:$4.75
-
Jun 28, 2023 (filed on Aug 30, 2023)Insider Name:Gathagan Bryan K.Ownership Type:Direct OwnershipSecurities:Non-Qualified Stock Options (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:15,000Price:$5.11
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 56 Evergreen Drive PORTLAND ME 04103 |
Tel: | N/A |
Website: | https://immucell.com |
IR: | See website |
Key People | ||
Michael F. Brigham President, Chief Executive Officer, Treasurer, Secretary, Director | Bobbi Jo Brockmann Vice President - Sales and Marketing, Director | Elizabeth Luttrell Williams Vice President - Manufacturing Operations |
Business Overview |
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing Immediate Immunity against each of the three causes of calf scours (E. coli, coronavirus, and rotavirus). |
Financial Overview |
For the three months ended 31 March 2024, ImmuCell Corp revenues increased from $3.4M to $7.3M. Net loss decreased 81% to $438K. Revenues reflect Re-Tain segment increase of 5% to $37K, United States segment increase from $3M to $6.3M, Other segment increase from $450K to $917K. Lower net loss reflects First Defense segment income totaling $1.6M vs. loss of $384K, Unallocated segment loss decrease of 6% to $562K. |
Employees: | 74 as of Mar 31, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $46.08M as of Mar 31, 2024 |
Annual revenue (TTM): | $21.28M as of Mar 31, 2024 |
EBITDA (TTM): | -$1.06M as of Mar 31, 2024 |
Net annual income (TTM): | -$3.90M as of Mar 31, 2024 |
Free cash flow (TTM): | -$2.77M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | $10.65M as of Mar 31, 2024 |
Shares outstanding: | 7,811,874 as of May 3, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |